The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Advanced Human Imaging (AHI) has signed a binding term sheet with European and Dutch mental health services provider Inter-Psy
  • The Netherlands-based business has developed Health i Check, a preventive screening platform which is due to go live on both iOS and Android devices
  • AHI wants to integrate its medical imaging platform with Health i Check and market it towards people improving their life via food and exercise changes
  • Under the term sheet, AHI and Inter-Psy are aiming to launch the combined product in October, with the hope of reaching 200,000 users within 12 months
  • Shares in Advanced Human Imaging are 1.6 per cent in the green at $1.59 each

Advanced Human Imaging (AHI) has signed a binding term sheet with European and Dutch mental health services provider Inter-Psy.

The Netherlands-based business has developed Health i Check, which works as a preventive screening platform.

The Health i Check app is due to go live on both iOS and Android devices in the Netherlands in June this year.

AHI wants to integrate its medical imaging platform with Inter-Psy’s product and market it towards people improving their life via food and exercise changes.

The integrated product is also being designed to work alongside government programs aimed at improving the health of overweight people.

Under the term sheet, AHI and Inter-Psy are aiming to launch their combined Health i Check product in October.

The Netherlands business has an initial target of reaching 200,000 users within 12 months, however, there’s no financial penalty if it fails to hit this mark.

AHI also specifies in today’s binding term sheet announcement it “does not expect any immediate material financial return” from the agreement.

Instead, AHI CEO Vlado Bosanac explained his company was keen to work with a business focussed on improving people’s lives.

“Providing at risk individuals with early warning signs and setting them on a healthier lifestyle course, not only benefits the individual, it has also been proven to lead to a longer, healthier lifespan,” he explained.

“This initiative is based on identifying the early warning signs, which our technology can assist in identification of the markers of such lifestyle diseases,” he said.

“This is the first of our partners to leverage government funded programs when providing our technology to end users free of charge,” the CEO added.

Shares in Advanced Human Imaging are trading 1.6 per cent in the green at $1.59 each at 12:42 pm AEST.

AHI by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…